Linked Life Data

9680372

Source:http://linkedlifedata.com/resource/pubmed/id/9680372

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1998-8-27
pubmed:abstractText
Approximately 40% of Hodgkin's disease (HD) cases in Western countries carry Epstein-Barr virus (EBV) in the malignant Hodgkin-Reed-Sternberg (H-RS) cells. HLA class I-restricted cytotoxic T lymphocytes (CTLs) with specificity for viral antigens expressed in H-RS cells therefore have therapeutic potential. However, a prerequisite for CTL therapy is that the tumor target be capable of processing and presenting endogenously expressed antigens via the transporter associated with antigen processing (TAP)-dependent HLA class I pathway. We have assessed the antigen-presenting phenotype of H-RS cells in two ways. First, immunohistochemical analysis of 38 HD biopsies showed that H-RS cells were uniformly TAP1/TAP2-positive and expressed HLA class I in the majority (18 of 24, 75%) of EBV-positive cases compared with only 4 of 14 (29%) of EBV-negative cases. Second, using a panel of 5 H-RS cell lines, we showed that 4 of 5 could process and present EBV proteins to HLA class I-restricted EBV-specific CTL clones. Others have reported that human interleukin-10 (IL-10), which is expressed by H-RS cells in the majority of EBV-positive HD cases, can abrogate CTL recognition in some circumstances. However, IL-10 pretreatment of the H-RS lines or of the EBV-specific CTLs had no such effect in this system. These results support the possibility that EBV-specific CTLs may be used to treat virus-positive HD.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0006-4971
pubmed:author
pubmed:copyrightInfo
Copyright 1998 by The American Society of Hematology.
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
92
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1020-30
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:9680372-ATP-Binding Cassette Transporters, pubmed-meshheading:9680372-Antigen Presentation, pubmed-meshheading:9680372-Antigen-Presenting Cells, pubmed-meshheading:9680372-Antigens, Viral, pubmed-meshheading:9680372-Biopsy, pubmed-meshheading:9680372-Epitopes, pubmed-meshheading:9680372-Herpesviridae Infections, pubmed-meshheading:9680372-Herpesvirus 4, Human, pubmed-meshheading:9680372-Histocompatibility Antigens Class I, pubmed-meshheading:9680372-Hodgkin Disease, pubmed-meshheading:9680372-Humans, pubmed-meshheading:9680372-Immunity, Cellular, pubmed-meshheading:9680372-Immunotherapy, pubmed-meshheading:9680372-Interleukin-10, pubmed-meshheading:9680372-Phenotype, pubmed-meshheading:9680372-Reed-Sternberg Cells, pubmed-meshheading:9680372-T-Lymphocytes, Cytotoxic, pubmed-meshheading:9680372-Tumor Cells, Cultured, pubmed-meshheading:9680372-Tumor Virus Infections, pubmed-meshheading:9680372-Viral Matrix Proteins
pubmed:year
1998
pubmed:articleTitle
Antigen presenting phenotype of Hodgkin Reed-Sternberg cells: analysis of the HLA class I processing pathway and the effects of interleukin-10 on epstein-barr virus-specific cytotoxic T-cell recognition.
pubmed:affiliation
CRC Institute for Cancer Studies, University of Birmingham, Birmingham, UK. s.p.lee@bham.ac.uk
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't